ClinicalTrials.gg
Status unknownNCT05046054Updated Jan 19, 2022

The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Propofol Injection

An interventional study of transcutaneous electrical nerve stimulation and Placebo transcutaneous electrical nerve stimulation in Transcutaneous Electrical Nerve Stimulation, Pain and Propofol Adverse Reaction, sponsored by Kyungpook National University Hospital. Status unknown at 1 site in South Korea. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-01-19.

Sponsored by Kyungpook National University Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2021, registered Sep 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
All
01

Study summary

Propofol, an intravenous sedative agent, frequently produces pain during injection. This study was designed to investigate whether transcutaneous electrical nerve stimulation could reduce pain during propofol injection.

in minimizing propofol injection pain.

Read the detailed description

Twenty min after transcutaneous electrical nerve stimulation, the electrodes were removed and propofol 0.5 mg/kg was administered at the rate of 0.5 ml/sec using syringe pump. Propofol injection pain was evaluated by a study blinded anesthesiologist using a four point scale: 0=no (negative response to questioning), 1=mild pain (pain reported only in response to questioning without any behavioral sings), 2=moderate pain (pain reported in response to questioning and accompanied by a behavioral signs or pain reported spontaneously without questioning, 3=severe pain (strong vocal response or response accompanied by facial grimacing, arm withdrawal or tears).

02

Conditions studied

  • Transcutaneous Electrical Nerve Stimulation
  • Pain
  • Propofol Adverse Reaction

Browse trials for

03

In context

Pain

2,450 studies on the registry are indexed under Pain; 945 are open to participants now.

This study's planned enrollment of 80 is above the median of 70 across 2,101 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Kyungpook National University Hospital is the lead sponsor of 80 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Exclusion criteria

Exclusion Criteria:

  • American Society of Anesthesiologists physical status classification > 3
  • Patient with a history of allergy to drugs
  • Patient who takes opioid, sedative, anticonvulsant
  • Patient with a history of neurologic disease and psychological disorders
  • patient with skin problem
  • Patient with pacemaker or electric medical device
  • pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    transcutaneous electrical nerve stimulation group

    Transcutaneous electrical nerve stimulation was givent via two electrodes on the venous cannulation site 20 min before propofol injection

    Device: transcutaneous electrical nerve stimulation

  • Placebo comparator
    control group

    No transcutaneous electrical nerve stimulation was not given via two electrodes on the venous cannulation site 20 min before propofol injection

    Device: Placebo transcutaneous electrical nerve stimulation

Interventions

  • Devicetranscutaneous electrical nerve stimulation

    transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection

  • DevicePlacebo transcutaneous electrical nerve stimulation

    Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection

06

What researchers measure

Primary outcomes

  1. pain during propofol injection

    Propofol injection pain was evaluated by a study blinded anesthesiologist using a four point scale

    Time frame: 15 seconds

07

Study locations

1 of 1 sites recruiting
  • Kyungpook National university hospital
    Daegu, 41944, South Korea
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jan 2022, 7 months after the start.

Of 1,253 non-industry interventional studies with no phase under Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 29. This study's planned 7 months is below that.

Counting every sponsor, half of 1,276 studies reached it within 11 months; a quarter within 5 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2021
First posted
Sep 16, 2021
StartActual
Jun 1, 2021
Primary completionEst.
Jan 30, 2022
CompletionEst.
Jan 30, 2022
Last update
Jan 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05046054
Lead sponsor
Kyungpook National University Hospital
Responsible party
Younghoon Jeon (Professor, Kyungpook National University Hospital) — Principal investigator
First posted
Sep 16, 2021
Start date
Jun 1, 2021
Primary completion
Jan 30, 2022 (estimated)
Completion
Jan 30, 2022 (estimated)
Last update
Jan 19, 2022

Study contacts

Younghoon Jeon, Dr
Contact
jeon68@gmail.com
+82534205863
Younghoon Jeon
Contact
jeon68@gmail.com
+82534205863
Younghoon Jeon
principal investigator · Kyungpook National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion